T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMA
1226
DELISTED
Comerica
CMA
| $15.5M | ﹤0.01% |
211,745
-13,441
| -6% | -$1.09M |
|
|
VSXY
1227
Victoria's Secret
VSXY
$7.24B
| $15.5M | ﹤0.01% |
553,842
-30,083
| -5% | -$1.3M |
|
1228
Bloomin' Brands
BLMN
$924M
| $15.4M | ﹤0.01% |
928,431
-207,475
| -18% | -$4.21M |
|
1229
RGC Resources
RGCO
$226M
| $15.4M | ﹤0.01% |
805,036
| – | – |
|
|
RETA
1230
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $15.2M | ﹤0.01% |
500,770
-61,979
| -11% | -$1.85M |
|
1231
Academy Sports + Outdoors
ASO
$3.03B
| $15M | ﹤0.01% |
423,394
-107,764
| -20% | -$3.94M |
|
1232
WEX
WEX
$6.78B
| $15M | ﹤0.01% |
96,379
+1,014
| +1% | +$166K |
|
|
IPG
1233
DELISTED
Interpublic Group of Companies
IPG
| $15M | ﹤0.01% |
544,349
-45,440
| -8% | -$1.44M |
|
1234
Dynatrace
DT
$14.7B
| $15M | ﹤0.01% |
379,169
+41,836
| +12% | +$1.67M |
|
1235
Eastman Chemical
EMN
$8.43B
| $14.9M | ﹤0.01% |
165,900
-17,738
| -10% | -$1.84M |
|
1236
Rapid Micro Biosystems
RPID
$85.3M
| $14.7M | ﹤0.01% |
3,427,154
-20,032
| -0.6% | -$93.2K |
|
1237
Supernus Pharmaceuticals
SUPN
$2.74B
| $14.7M | ﹤0.01% |
508,748
-7,479
| -1% | -$214K |
|
|
AGNT
1238
AGNT Inc
AGNT
$752M
| $14.6M | ﹤0.01% |
1,242,569
-1,616,001
| -57% | -$23.4M |
|
1239
Nordson
NDSN
$17.3B
| $14.6M | ﹤0.01% |
71,962
-4,757
| -6% | -$1.01M |
|
1240
ePlus
PLUS
$2.31B
| $14.5M | ﹤0.01% |
273,573
+19,149
| +8% | +$1.07M |
|
1241
Hasbro
HAS
$13.6B
| $14.4M | ﹤0.01% |
175,932
-12,179
| -6% | -$1.06M |
|
1242
Celldex Therapeutics
CLDX
$3.35B
| $14.4M | ﹤0.01% |
533,402
-520,923
| -49% | -$15.1M |
|
1243
Innovative Industrial Properties
IIPR
$1.67B
| $14.4M | ﹤0.01% |
130,729
-45,889
| -26% | -$6.51M |
|
1244
Petrobras
PBR
$115B
| $14.3M | ﹤0.01% |
1,221,683
| – | – |
|
1245
Ambev
ABEV
$43.8B
| $14.2M | ﹤0.01% |
5,662,200
+362,000
| +7% | +$1.03M |
|
1246
National Vision
EYE
$1.51B
| $14.2M | ﹤0.01% |
516,013
-206,186
| -29% | -$6.79M |
|
1247
Snap-on
SNA
$20.9B
| $14.2M | ﹤0.01% |
71,928
-7,234
| -9% | -$1.54M |
|
1248
Flywire
FLYW
$2.22B
| $14.2M | ﹤0.01% |
802,740
+539,758
| +205% | +$12.5M |
|
1249
Pultegroup
PHM
$24.9B
| $14.1M | ﹤0.01% |
356,255
-43,076
| -11% | -$1.81M |
|
1250
First American
FAF
$7.56B
| $14.1M | ﹤0.01% |
265,502
-370
| -0.1% | -$21.5K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.